Pds biotech announces submission of phase 3 protocol to fda to initiate versatile-003 trial

Versatile-003 will evaluate pds0101 in combination with keytruda® in recurrent or metastatic hpv16-positive head and neck cancer
PDSB Ratings Summary
PDSB Quant Ranking